Pharmaceuticals, Biotechnology and Life Sciences
Sales & Marketing Expense as a Percentage of Total Revenue Declined to 41.7% for the three months ended June 30,…
Milestone Pharmaceuticals gets to advance its pivotal program of etripamil, its novel, potent and short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT), the company said in an quarter and half year financial update.
Eli Lilly’s Taltz met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, testing Taltz versus TREMFYA (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has approved variations to broaden the use of Imbruvica® (ibrutinib) in two indications.
A new forensic authentication feature for pharmaceutical labels is offered by Schreiner MediPharm in cooperation with Applied DNA Sciences: SigNature® DNA is a high-security feature based on DNA markers with which pharmaceutical manufacturers can protect their products against counterfeiting and patients against potential health risks. DNA markers are deemed to be impossible to counterfeit and recognized as forensic authentication evidence in courts of law.
Initiated a Non-IND, IRB-Approved Clinical Study for AXA1957 in adolescent subjects with NAFLD Announced the publication in Frontiers of data…
Presented updated data from Phase 2 monotherapy arm of DeCidE1 study at ASCO 2019; DPX-Survivac exhibited durable clinical benefit with…
SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe,…
AstraZeneca Tagrisso in a phase 3 trial, with previously-untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations, brought positive overall survival (OS) results.
Novo Nordisk’s operating profit increased by 12% in Danish kroner and by 6% at constant exchange rates (CER) in the first six months of 2019 with reported sales within Diabetes and obesity increased by 10% to DKK 50.1 billion (6% at CER), driven by Diabetes growing 4% at CER and Obesity growing 56% at CER. Sales within Biopharmaceuticals increased by 7% to DKK 9.3 billion (3% at CER).